Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

Atherosclerosis

Volumn 253, Issue , 2016, Pages 194-208

  Chruściel, Piotr ^a   Sahebkar, Amirhossein ^b,c   Rembek Wieliczko, Magdalena ^a,h   Serban, Maria Corina ^d,e   Ursoniu, Sorin ^e   Mikhailidis, Dimitri P ^f   Jones, Steven R ^g   Mosteoru, Svetlana ^e   Blaha, Michael J ^g   Martin, Seth S ^g   Rysz, Jacek ^a,h   Toth, Peter P ^g,i   Lip, Gregory Y H ^j   Pencina, Michael J ^k   Ray, Kausik K ^l   Banach, Maciej ^a,h  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Healthy Ageing Research Centre (HARC)   (Poland)

ⁱ CGH MEDICAL CENTER   (United States)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Adiponectin; Hydroxymethylglutaryl CoA reductase inhibitors; Meta analysis; Statins

Indexed keywords

ADIPONECTIN; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ADIPOQ PROTEIN, HUMAN; QUINOLINE DERIVATIVE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

ADIPONECTIN; ADULT; AGED; ATORVASTATIN CALCIUM; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 84992125333     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.07.897     Document Type: Article

References (80)

1. [1] Tilg, H., Moschen, A.R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6 (2006), 772–783.
2. [2] Jung, U.J., Choi, M.-S., Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15 (2014), 6184–6223.
3. [3] Zhang, L., Li, M.-M., Corcoran, M., et al. Essential roles of insulin, AMPK signaling and lysyl and prolyl hydroxylases in the biosynthesis and multimerization of adiponectin. Mol. Cell. Endocrinol. 399 (2015), 164–177.
4. [4] Park, S.E., Park, C.-Y., Sweeney, G., Biomarkers of insulin sensitivity and insulin resistance: past, present and future. Crit. Rev. Clin. Lab. Sci. 52 (2015), 180–190.
5. [5] Heid, I.M., Henneman, P., Hicks, A., et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis 208 (2010), 412–420.
6. [6] Khan, U.I., Wang, D., Sowers, M.R., et al. Race–ethnic differences in adipokine levels: the Study of Women's Health across the Nation (SWAN). Metabol. Clin. Exp. 61 (2012), 1261–1269.
7. [7] Karastergiou, K., The interplay between sex, ethnicity, and adipose tissue characteristics. Curr. Obes. Rep., 2015, 1–10.
8. [8] Stumvoll, M., Tschritter, O., Fritsche, A., et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51 (2002), 37–41.
9. [9] Kadowaki, T., Yamauchi, T., Kubota, N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116 (2006), 1784–1792.
10. [10] Greenhill, C., Epigenetics: obesity-induced hypermethylation of adiponectin gene, nature reviews. Endocrinology, 11, 2015 504–504.
11. [11] Ohashi, K., Yuasa, D., Shibata, R., et al. Adiponectin as a target in obesity-related inflammatory state, endocrine. Metabol. Immune Disorders Drug Targets Formerly Curr. Drug Targets ImmuneEndocr. Metabol. Disord. 15 (2015), 145–150.
12. [12] Stępień, M., Stępień, A., Banach, M., et al. New obesity indices and adipokines in normotensive patients and patients with hypertension comparative pilot analysis. Angiology 65 (2014), 333–342.
13. [13] Stępień, M., Wlazeł, R.N., Paradowski, M., et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo-and hypertensive patients–pilot study. Arch. Med. Sci. 8 (2012), 431–436.
14. [14] Stepien, M., Rosniak-Bak, K., Paradowski, M., et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med. Sci. Monit. Basic Res. 17 (2011), PR13–PR18.
15. [15] Nigro, E., Scudiero, O., Monaco, M.L., et al. New insight into adiponectin role in obesity and obesity-related diseases. BioMed Res. Int., 2014, 2014, 658913.
16. [16] Hui, X., Lam, K.S., Vanhoutte, P.M., et al. Adiponectin and cardiovascular health: an update. Br. J. Pharmacol. 165 (2012), 574–590.
17. [17] Brochu-Gaudreau, K., Rehfeldt, C., Blouin, R., et al. Adiponectin action from head to toe. Endocrine 37 (2010), 11–32.
18. [18] Hossain, M.M., Mukheem, A., Kamarul, T., The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin. Life Sci. 135 (2015), 55–67.
19. [19] Lee, S., Hong, H., Han, T., et al. Aerobic training increases the expression of adiponectin receptor genes in the peripheral blood mononuclear cells of young men. Biol. sport, 32, 2015, 181.
20. [20] Banach, M., Serban, C., Sahebkar, A., et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med., 13, 2015, 229.
21. [21] Sahebkar, A., Kotani, K., Serban, C., et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis 241 (2015), 433–442.
22. [22] Banach, M., Malodobra-Mazur, M., Gluba, A., et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr. Pharm. Des. 19 (2013), 4904–4912.
23. [23] Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
24. [24] Higgins, J., Green, S., Cochrane handbook for systematic reviews of interventions version 5.1. 0. Cochrane Collab., 5, 2011.
25. [25] Borenstein, M., Hedges, L., Higgins, J., et al. Comprehensive Meta-analysis Version 2. 2005, Biostat, Englewood, NJ, 104.
26. [26] Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 5, 2005, 13.
27. [27] Sutton, A.J., Abrams, K.R., Jones, D.R., et al. Methods for Meta-analysis in Medical Research. 2000, J. Wiley Chichester, New York.
28. [28] Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
29. [29] Sahebkar, A., Watts, G.F., Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis 230 (2013), 110–120.
30. [30] Jin, D., Sun, J., Huang, J., et al. Peroxisome proliferator-activated receptor gamma enhances adiponectin secretion via up-regulating DsbA-L expression. Mol. Cell Endocrinol. 411 (2015), 97–104.
31. [31] Serban, C., Sahebkar, A., Ursoniu, S., et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci. Rep., 5, 2015, 9902.
32. [32] Sahebkar, A., Serban, C., Mikhailidis, D.P., et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb. Haemost. 114 (2015), 546–557.
33. [33] Fantuzzi, G., Adiponectin and inflammation: consensus and controversy. J. Allergy Clin. Immunol. 121 (2008), 326–330.
34. [34] Keech, A., Colquhoun, D., Best, J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003), 2713–2721.
35. [35] Rajpathak, S.N., Kumbhani, D.J., Crandall, J., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes care 32 (2009), 1924–1929.
36. [36] Kei, A., Rizos, E.C., Elisaf, M., Statin use in prediabetic patients: rationale and results to date. Ther. Adv. Chronic Dis. 6 (2015), 246–251.
37. [37] Elfakhani, M., Torabi, S., Hussein, D., et al. Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes. Exp. Biol. Med. 239 (2014), 293–301.
38. [38] Barylski, M., Nikolic, D., Banach, M., et al. Statins and new-onset diabetes. Curr. Pharm. Des. 20 (2014), 3657–3664.
39. [39] Amin, R., Chen, H.-Q., Tannous, M., et al. Inhibition of glucose-and calcium-induced insulin secretion from βTC3 cells by novel inhibitors of protein isoprenylation. J. Pharmacol. Exp. Ther. 303 (2002), 82–88.
40. [40] Banach, M., Serban, C., Ursoniu, S., et al. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. Pharmacol. Res. 99 (2015), 329–336.
41. [41] Mabuchi, H., Higashikata, T., Kawashiri, M., et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J. Atheroscler. Thromb. 12 (2005), 111–119.
42. [42] Chamberlain, L.H., Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 507 (2001), 357–361.
43. [43] Abel, E.D., Peroni, O., Kim, J.K., et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409 (2001), 729–733.
44. [44] Maedler, K., Sergeev, P., Ehses, J.A., et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 8138–8143.
45. [45] Kostapanos, M.S., Milionis, H.J., Elisaf, M.S., An overview of the extra-lipid effects of rosuvastatin. J. Cardiovasc Pharmacol. Ther. 13 (2008), 157–174.
46. [46] Arnaboldi, L., Corsini, A., Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atherosclerosis 16 (2015), 1–27 Supplements.
47. [47] McTaggart, F., Comparative pharmacology of rosuvastatin. Atherosclerosis 4 (2003), 9–14 Supplements.
48. [48] Chapman, M., Orsoni, A., Robillard, P., et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr. Med. Res. Opin. 30 (2014), 775–784.
49. [49] Fan, L.H., He, Y., Xu, W., et al. Adiponectin may be a biomarker of early atherosclerosis of smokers and decreased by nicotine through KATP channel in adipocytes. Nutr. (Burbank, Los Angel. Cty. Calif.) 31 (2015), 955–958.
50. [50] Gazzerro, P., Proto, M.C., Gangemi, G., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64 (2012), 102–146.
51. [51] Buldak, L., Dulawa-Buldak, A., Labuzek, K., et al. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int. J. Clin. Pharmacol. Ther. 50 (2012), 805–813.
52. [52] Chan, K.C., Chou, H.H., Huang, C.N., et al. Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level. Clin. Cardiol. 31 (2008), 253–258.
53. [53] Devaraj, S., Siegel, D., Jialal, I., Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am. J. Cardiol. 100 (2007), 1397–1399.
54. [54] Doh, F.M., Chang, T.-I., Koo, H.M., et al. The effect of HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis. Cardiovasc. drugs Ther. 26 (2012), 501–509.
55. [55] El-Barbary, A.M., Hussein, M.S., Rageh, E.M., et al. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J. Rheumatol. 38 (2011), 229–235.
56. [56] Fichtenbaum, C.J., Yeh, T.-M., Evans, S.R., et al. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J. Clin. Lipidol. 4 (2010), 279–287.
57. [57] Forst, T., Pfützner, A., Lübben, G., et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study. Metabolism 56 (2007), 491–496.
58. [58] Gannagé-Yared, M.-H., Azar, R.R., Amm-Azar, M., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54 (2005), 947–951.
59. [59] Gouni-Berthold, I., Berthold, H.K., Chamberland, J.P., et al. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin. Endocrinol. 68 (2008), 536–541.
60. [60] Kim, J.H., Lee, M.R., Shin, J.A., et al. Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus. Atherosclerosis 227 (2013), 355–359.
61. [61] Koh, K.K., Quon, M.J., Han, S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol. 45 (2005), 1649–1653.
62. [62] Koh, K.K., Quon, M.J., Han, S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45 (2005), 1088–1093.
63. [63] Koh, K.K., Quon, M.J., Han, S.H., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204 (2009), 483–490.
64. [64] Koh, K.K., Quon, M.J., Han, S.H., et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J. Am. Coll. Cardiol. 55 (2010), 1209–1216.
65. [65] Koh, K.K., Quon, M.J., Han, S.H., et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 146 (2011), 319–325.
66. [66] Koh, K.K., Quon, M.J., Sakuma, I., et al. Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia. Int. J. Cardiol. 146 (2011), 434–437.
67. [67] Koh, K.K., Quon, M.J., Sakuma, I., et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int. J. Cardiol. 166 (2013), 509–515.
68. [68] Koh, K.K., Lim, S., Choi, H., et al. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes 62 (2013), 3547–3552.
69. [69] Koh, K.K., Quon, M.J., Han, S.H., et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31 (2008), 776–782.
70. [70] Krysiak, R., Zmuda, W., Okopien, B., The effect of simvastatin–ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc. Ther. 32 (2014), 40–46.
71. [71] Koh, K.K., Quon, M.J., Han, S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004), 3687–3692.
72. [72] Nakamura, T., Kodama, Y., Takano, H., et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 193 (2007), 449–451.
73. [73] Nomura, S., Inami, N., Shouzu, A., et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 20 (2009), 16–22.
74. [74] Roberto, C., Pasquale, P., Simona, B., et al. Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis 213 (2010), 225–234.
75. [75] Sawara, Y., Takei, T., Uchida, K., et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern. Med. 47 (2008), 1505–1510.
76. [76] Shetty, G.K., Economides, P.A., Horton, E.S., et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27 (2004), 2450–2457.
77. [77] Sugiyama, S., Fukushima, H., Kugiyama, K., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194 (2007), e43–e51.
78. [78] van Hoek, M., van Tol, A., van Vark-Van der Zee, L., et al. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes*. Curr. Med. Res. Opinion 25 (2008), 93–101.
79. [79] Yokoyama, H., Saito, S., Daitoku, K., et al. Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease. Fundam. Clin. Pharmacol. 25 (2011), 378–387.
80. [80] Hu, Y., Tong, G., Xu, W., et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diabetes Vasc. Dis. Res. 6 (2009), 262–268.